<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017769</url>
  </required_header>
  <id_info>
    <org_study_id>2012-100</org_study_id>
    <nct_id>NCT02017769</nct_id>
  </id_info>
  <brief_title>MRI in Diagnosing and Monitoring CIDP</brief_title>
  <official_title>Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to study whether MRI can be useful in diagnosing and monitoring patients with CIDP in&#xD;
      maintenance treatment with immunoglobulin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic inflammatory neuropathies such as chronic inflammatory demyelinating&#xD;
      polyradiculoneuropathy (CIDP) can be successfully treated with immunoglobulin either&#xD;
      intravenously (IVIG) or subcutaneously (SCIG).&#xD;
&#xD;
      CIDP is diagnosed by electrophysiology which is time-consuming and unpleasant for the&#xD;
      patient.&#xD;
&#xD;
      New techniques suggest that Magnetic Resonance Imaging (MRI) and ultrasound imaging can be&#xD;
      used to detect injuries in the peripheral nerves&#xD;
&#xD;
      We want to study if MRI and ultrasound is able to detect damages in peripheral nerves, nerve&#xD;
      roots and plexus in patients with CIDP.&#xD;
&#xD;
      Moreover, we want to compare these findings to healthy matched controls and to see if&#xD;
      treatment with immunoglobulin changes findings in MRI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DTI changes in nerves and muscles</measure>
    <time_frame>At enrolment</time_frame>
    <description>Diffusion Tension Imaging (DTI) in peripheral nerves and muscles in the lower extremities in CIDP patients treated with SCIG will be compared to healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI findings between treated and untreated CIDP patients</measure>
    <time_frame>All patients are examined at enrolment. Untreated patients are re-examined after 4 months of treatment</time_frame>
    <description>Comparing changes in MTR and DTI between CIDP patients treated with subcutaneous immunoglobulin to those untreated.&#xD;
The untreated patients will be examined again after 4 months of treatment with immunoglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing clinical findings to MRI</measure>
    <time_frame>At enrolment</time_frame>
    <description>Clinical evaluation by:&#xD;
Isokinetic dynamometry Clinical MRC score&#xD;
These findings wil be compared to findings on MRI to assess an eventual correlation</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyradiculoneuropathy</condition>
  <arm_group>
    <arm_group_label>CIDP - treated</arm_group_label>
    <description>Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy, gender and age matched controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIDP - untreated</arm_group_label>
    <description>Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with subcutaneous immunoglobulin for CIDP are invited to participate. They&#xD;
        will be recruited from the outpatient clinic at Department of Neurology in Aarhus, Odense&#xD;
        and at Rigshospitalet (Copenhagen)&#xD;
&#xD;
        Healthy controls will be recruited by public announcement&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        CIDP patients&#xD;
&#xD;
          -  Age &gt; 18 and &lt; 80 years&#xD;
&#xD;
          -  Diagnosed with definite and probable CIDP and fulfilling the European Federation of&#xD;
             Neurological Sciences/Peripheral Nerve Society (EFNS/PNS) criteria&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  Age &gt; 18 and &lt; 80 years&#xD;
&#xD;
          -  No neurological disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 80 years&#xD;
&#xD;
          -  Contraindications to MRI&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Other cause of neuropathy (incl. pressure neuropathy)&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Andersen, Prof, DMSc</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneous immunoglobulin</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

